Look Beyond the Hype

Not All AI Is Created Equal

Discover the Unrivaled Power of ProFound AI®

Book a Meeting

World-class technology. ProFound outcomes.

As a radiologist, you understand the importance of looking closely to determine the truth.

For more than 20 years, iCAD has built a legacy of global leadership delivering transformative innovations built on artificial intelligence to detect cancer earlier. Our complete focus is on empowering you with state-of-the-art deep-learning technologies expertly engineered to optimize operational efficiency, clinician confidence and patient outcomes.

We invite you to look beyond the hype and experience ProFound confidence in your AI solutions, without compromise.

From the world leader in artificial intelligence for breast imaging, discover the ProFound impact iCAD’s award-winning portfolio of cancer detection, density assessment, and risk evaluation solutions can have on your reading workflow.

Breast AI SuiteProFound AI for Digital Breast TomosynthesisProFound AI for 2D MammographyProFound AI
PowerLook Density Assessment

AccurateUnrivaled by any other AI solution available today, ProFound AI® improves radiologists’ sensitivity by 8%, and reduces false positives
and unnecessary patient recall rates by 7.2%.
The latest version offers up to a 10% incremental improvement in specificity performance* while maintaining an industry-leading high sensitivity level.*Standalone performance
EfficientProFound AI delivers unmatched, clinically proven time-savings benefits to radiologists, slashing reading time by 52.7%.Further, Certainty of Finding and Case Scores assist in prioritizing caseload and clinical decision-making, reducing physician burnout.Multi-VendorWith thousands of installations worldwide, ProFound AI offers multi-vendor compatibility and seamlessly integrates into the diagnostic process.Our commitment to integrate with all major mammography system vendors and enterprise-wide viewing applications empowers hospitals and imaging centers everywhere with a proven, standardized AI solution primed to scale.Now compatible with
Hologic Clarity HD™!
FlexibleToday’s unprecedented screening challenges call for unparalleled AI solutions, streamlining workflow and elevating outcomes.ProFound AI flexibly integrates with major PACS, offering an intuitive, system-wide solution for improved workflow and decision support in any reading environment.ScalableWith market leading agility, ProFound AI offers a practical enterprise-wide solution with powerful results.With access to our complete portfolio of cancer detection, density assessment and risk evaluation solutions on one centralized server, streamlined deployment of state-of-the-art breast imaging technology at scale is simple.EquitableNow available for 2D and 3D mammography, ProFound AI® Risk is the world’s first clinical decision support tool that provides an accurate short-term, breast cancer risk estimation that is truly personalized for each woman.Specifically designed to factor in racial and ethnic backgrounds, ProFound AI Risk offers an inclusive, first-in-kind approach to precision screening.

What’s better than Clarity? Certainty.

Experience high-performance AI
for high-resolution imaging.

Now compatible with the Hologic Clarity HD™ high-resolution imaging suite!

Expert insights today. ProFound performance tomorrow.

A ProFound Legacy of Leadership

2+ decades
of AI market leadership
global patents
7,000+ installations worldwideThe latest version of ProFound AI was developed using more than 5 million images from 30,000 cases, including almost 8,000 biopsy-proven cancers, and is continuously improving.

Trust the proven leader in Breast AI.

Book a meeting to learn more about how ProFound AI can help you meet your goals.

© iCAD Inc.  All rights reserved.  iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.

Facebook icon Twitter icon LinkedIn icon